YH013 is a novel fully-human bsADC generated from the RenLite® platform that target EGFR and c-Met, which are co-expressed in a wide range of tumor types By targeting dual TAAs, YH013 showed increased tumor cell specificity and higher internalization in EGFR/MET co-expressing tumor cells where the antibody binding capacity of EGFR and c-Met were similar The BsAb backbone of YH013 molecule is constructed using RenLite® common light chain plus knobs-into-holes (KIH) technologies allow for efficient BsAb assembly and great CMC developability YH013 showed outstanding and dose-dependent anti-tumor activity in both CDX and PDX models than benchmark antibodies at lower doses